These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 33471959)
1. CRISPR/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer. Chen A; Wen S; Liu F; Zhang Z; Liu M; Wu Y; He B; Yan M; Kang T; Lam EW; Wang Z; Liu Q Cancer Commun (Lond); 2021 Feb; 41(2):121-139. PubMed ID: 33471959 [TBL] [Abstract][Full Text] [Related]
2. Aurora B phosphorylates centromeric MCAK and regulates its localization and microtubule depolymerization activity. Lan W; Zhang X; Kline-Smith SL; Rosasco SE; Barrett-Wilt GA; Shabanowitz J; Hunt DF; Walczak CE; Stukenberg PT Curr Biol; 2004 Feb; 14(4):273-86. PubMed ID: 14972678 [TBL] [Abstract][Full Text] [Related]
3. Co-inhibition of Aurora A and Haspin kinases enhances survivin blockage and p53 induction for mitotic catastrophe and apoptosis in human colorectal cancer. Lin CI; Chen ZC; Chen CH; Chang YH; Lee TC; Tang TT; Yu TW; Yang CM; Tsai MC; Huang CC; Yang TW; Lin CC; Wang RH; Chiou GY; Jong YJ; Chao JI Biochem Pharmacol; 2022 Dec; 206():115289. PubMed ID: 36241092 [TBL] [Abstract][Full Text] [Related]
4. Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition. Huang M; Feng X; Su D; Wang G; Wang C; Tang M; Paulucci-Holthauzen A; Hart T; Chen J Oncogene; 2020 May; 39(21):4312-4322. PubMed ID: 32300176 [TBL] [Abstract][Full Text] [Related]
5. Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition. Zhang Z; Zeng D; Zhang W; Chen A; Lei J; Liu F; Deng B; Zhuo J; He B; Yan M; Lei X; Wang S; Lam EW; Liu Q; Wang Z Cell Death Dis; 2021 Sep; 12(10):893. PubMed ID: 34593753 [TBL] [Abstract][Full Text] [Related]
6. A perikinetochoric ring defined by MCAK and Aurora-B as a novel centromere domain. Parra MT; Gómez R; Viera A; Page J; Calvente A; Wordeman L; Rufas JS; Suja JA PLoS Genet; 2006 Jun; 2(6):e84. PubMed ID: 16741559 [TBL] [Abstract][Full Text] [Related]
7. Aurora B is enriched at merotelic attachment sites, where it regulates MCAK. Knowlton AL; Lan W; Stukenberg PT Curr Biol; 2006 Sep; 16(17):1705-10. PubMed ID: 16950107 [TBL] [Abstract][Full Text] [Related]
8. Spatiotemporal dynamics of Aurora B-PLK1-MCAK signaling axis orchestrates kinetochore bi-orientation and faithful chromosome segregation. Shao H; Huang Y; Zhang L; Yuan K; Chu Y; Dou Z; Jin C; Garcia-Barrio M; Liu X; Yao X Sci Rep; 2015 Jul; 5():12204. PubMed ID: 26206521 [TBL] [Abstract][Full Text] [Related]
9. Aurora B regulates MCAK at the mitotic centromere. Andrews PD; Ovechkina Y; Morrice N; Wagenbach M; Duncan K; Wordeman L; Swedlow JR Dev Cell; 2004 Feb; 6(2):253-68. PubMed ID: 14960279 [TBL] [Abstract][Full Text] [Related]
10. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines. Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033 [TBL] [Abstract][Full Text] [Related]
12. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells. Inchanalkar S; Deshpande NU; Kasherwal V; Jayakannan M; Balasubramanian N Mol Pharm; 2018 Aug; 15(8):3046-3059. PubMed ID: 29863884 [TBL] [Abstract][Full Text] [Related]
13. NuSAP modulates the dynamics of kinetochore microtubules by attenuating MCAK depolymerisation activity. Li C; Zhang Y; Yang Q; Ye F; Sun SY; Chen ES; Liou YC Sci Rep; 2016 Jan; 6():18773. PubMed ID: 26733216 [TBL] [Abstract][Full Text] [Related]
14. MCAK facilitates chromosome movement by promoting kinetochore microtubule turnover. Wordeman L; Wagenbach M; von Dassow G J Cell Biol; 2007 Dec; 179(5):869-79. PubMed ID: 18039936 [TBL] [Abstract][Full Text] [Related]
15. An inner centromere protein that stimulates the microtubule depolymerizing activity of a KinI kinesin. Ohi R; Coughlin ML; Lane WS; Mitchison TJ Dev Cell; 2003 Aug; 5(2):309-21. PubMed ID: 12919681 [TBL] [Abstract][Full Text] [Related]
16. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer. Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164 [TBL] [Abstract][Full Text] [Related]
17. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage. Li C; Liao J; Wang X; Chen FX; Guo X; Chen X Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021 [TBL] [Abstract][Full Text] [Related]
18. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439 [TBL] [Abstract][Full Text] [Related]
19. Aurora B phosphorylates multiple sites on mitotic centromere-associated kinesin to spatially and temporally regulate its function. Zhang X; Lan W; Ems-McClung SC; Stukenberg PT; Walczak CE Mol Biol Cell; 2007 Sep; 18(9):3264-76. PubMed ID: 17567953 [TBL] [Abstract][Full Text] [Related]
20. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]